<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="ccr36689" xml:lang="en" article-type="case-report">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Clin Case Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Clin Case Rep</journal-id>
      <journal-id journal-id-type="doi">10.1002/(ISSN)2050-0904</journal-id>
      <journal-id journal-id-type="publisher-id">CCR3</journal-id>
      <journal-title-group>
        <journal-title>Clinical Case Reports</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2050-0904</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">36514469</article-id>
      <article-id pub-id-type="pmc">9731158</article-id>
      <article-id pub-id-type="doi">10.1002/ccr3.6689</article-id>
      <article-id pub-id-type="publisher-id">CCR36689</article-id>
      <article-id pub-id-type="other">CCR3-2022-09-2022.R1</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Case Report</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>
<styled-content style="fixed-case" toggle="no">CASQ1</styled-content>&#x2010;related myopathy: The first report from China and the literature review</article-title>
      </title-group>
      <contrib-group>
        <contrib id="ccr36689-cr-0001" contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Kai&#x2010;Yue</given-names>
          </name>
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3796-0139</contrib-id>
          <xref rid="ccr36689-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="ccr36689-cr-0002" contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Geng&#x2010;Jian</given-names>
          </name>
          <xref rid="ccr36689-aff-0002" ref-type="aff">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="ccr36689-cr-0003" contrib-type="author">
          <name>
            <surname>Duan</surname>
            <given-names>Hui&#x2010;Qian</given-names>
          </name>
          <xref rid="ccr36689-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="ccr36689-cr-0004" contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Qiu&#x2010;Xiang</given-names>
          </name>
          <xref rid="ccr36689-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="ccr36689-cr-0005" contrib-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>Kun</given-names>
          </name>
          <xref rid="ccr36689-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="ccr36689-cr-0006" contrib-type="author">
          <name>
            <surname>Xu</surname>
            <given-names>Li&#x2010;Qun</given-names>
          </name>
          <xref rid="ccr36689-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="ccr36689-cr-0007" contrib-type="author" corresp="yes">
          <name>
            <surname>Yang</surname>
            <given-names>Huan</given-names>
          </name>
          <xref rid="ccr36689-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
          <address>
            <email>yangh69@126.com</email>
          </address>
        </contrib>
        <contrib id="ccr36689-cr-0008" contrib-type="author" corresp="yes">
          <name>
            <surname>Luo</surname>
            <given-names>Yue&#x2010;Bei</given-names>
          </name>
          <xref rid="ccr36689-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
          <address>
            <email>yuebei507@csu.edu.cn</email>
          </address>
        </contrib>
      </contrib-group>
      <aff id="ccr36689-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology, Xiangya Hospital</named-content>
<institution>Central South University</institution>
<city>Changsha</city>
<country country="CN">China</country>
</aff>
      <aff id="ccr36689-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Dermatology</named-content>
<institution>Affiliated Hospital of Zunyi Medical University</institution>
<city>Zunyi</city>
<country country="CN">China</country>
</aff>
      <author-notes>
        <corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>
Yue&#x2010;Bei Luo, Huan Yang, Department of Neurology, Xiangya Hospital, Central South University, Xiangya Road, Kaifu District, Changsha 410008, China.<break/>
Email: <email>yuebei507@csu.edu.cn</email> (Y.&#x2010;B. L.); <email>yangh69@126.com</email> (H. Y.)<break/>
</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>08</day>
        <month>12</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>12</month>
        <year>2022</year>
      </pub-date>
      <volume>10</volume>
      <issue seq="590">12</issue>
      <issue-id pub-id-type="doi">10.1002/ccr3.v10.12</issue-id>
      <elocation-id>e6689</elocation-id>
      <history>
<date date-type="rev-recd"><day>31</day><month>10</month><year>2022</year></date>
<date date-type="received"><day>28</day><month>9</month><year>2022</year></date>
<date date-type="accepted"><day>11</day><month>11</month><year>2022</year></date>
</history>
      <permissions>
        <!--&#x000a9; 2022 John Wiley & Sons Ltd.-->
        <copyright-statement content-type="article-copyright">&#xA9; 2022 The Authors. <italic toggle="yes">Clinical Case Reports</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x2010;commercial and no modifications or adaptations are made.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="file:CCR3-10-e6689.pdf"/>
      <abstract>
        <title>Abstract</title>
        <p>Calsequestrin 1 (CASQ1) is the most crucial Ca<sup>2+</sup> binding protein localized in the sarcoplasmic reticulum (SR) of skeletal muscle. With high capacity and low affinity for Ca<sup>2+</sup>, CASQ1 plays a significant role in maintaining a large amount of Ca<sup>2+</sup> necessary for muscle contraction. However, only five mutations in <italic toggle="no">CASQ1</italic> have been identified to date. Here, we report a 42&#x2010;year&#x2010;old Chinese female patient who presented with a 12&#x2009;years history of slowly progressive upper limb weakness, predominantly affecting distal muscles, which was uncommon comparing to other CASQ1&#x2010;related patients. Next&#x2010;generation sequencing (NGS) analysis revealed a novel heterozygous mutation (c.766G&#x2009;&gt;&#x2009;A, p.Val256Met) in <italic toggle="no">CASQ1</italic>. Functional studies confirmed the likely pathogenicity of this variant. Muscle histopathology revealed rare optically empty vacuoles in myofibers and atypical eosinophilic granules in the cytoplasm, which has not been observed before. We also performed a literature review on all the pathogenic mutations in <italic toggle="no">CASQ1</italic> and summarized their genetic and clinical characteristics. This is the first report on CASQ1&#x2010;related myopathy from China, further expanding the mutation spectrum of <italic toggle="no">CASQ1</italic> gene and provides new insights into the function of CASQ1.</p>
      </abstract>
      <abstract abstract-type="graphical">
        <p>The p.Val256Met variant in CASQ1 can cause slowly progressive muscle weakness that is confined to distal upper limbs. Atypical eosinophilic granules on muscle pathology might be a new pathological phenotype of CASQ1&#x2010;related myopathy.<boxed-text position="anchor" content-type="graphic" id="ccr36689-blkfxd-0001"><graphic xlink:href="CCR3-10-e6689-g001.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="ccr36689-kwd-0001">
          <italic toggle="no">CASQ1</italic>
        </kwd>
        <kwd id="ccr36689-kwd-0002">eosinophilic granules</kwd>
        <kwd id="ccr36689-kwd-0003">muscle pathology</kwd>
        <kwd id="ccr36689-kwd-0004">myopathy</kwd>
        <kwd id="ccr36689-kwd-0005">neuromuscular disorder</kwd>
      </kwd-group>
      <funding-group>
        <award-group id="funding-0001">
          <funding-source>
            <institution-wrap>
              <institution>National Natural Science Foundation of China
</institution>
              <institution-id institution-id-type="doi">10.13039/501100001809</institution-id>
            </institution-wrap>
          </funding-source>
          <award-id>81601094</award-id>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="3"/>
        <table-count count="1"/>
        <page-count count="6"/>
        <word-count count="2612"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>December 2022</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.2 mode:remove_FC converted:08.12.2022</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <p content-type="self-citation">
<mixed-citation publication-type="journal" id="CCR36689-cit-2001">
<string-name>
<surname>Zhang</surname>
<given-names>K&#x2010;Y</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>G&#x2010;J</given-names>
</string-name>, <string-name>
<surname>Duan</surname>
<given-names>H&#x2010;Q</given-names>
</string-name>, et al. <article-title>
<styled-content style="fixed-case" toggle="no">CASQ1</styled-content>&#x2010;related myopathy: The first report from China and the literature review</article-title>. <source>Clin Case Rep</source>. <year>2022</year>;<volume>10</volume>:<elocation-id>e06689</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/ccr3.6689</pub-id>
</mixed-citation>
</p>
    </notes>
  </front>
  <body id="ccr36689-body-0001">
    <sec id="ccr36689-sec-0001">
      <label>1</label>
      <title>INTRODUCTION</title>
      <p>Calsequestrin (CASQ) is the most crucial Ca<sup>2+</sup> binding protein localized in the sarcoplasmic reticulum (SR) of skeletal and cardiac muscle.<xref rid="ccr36689-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> CASQ is present in all vertebrates and has two isoforms, CASQ1 and CASQ2. CASQ1 is only expressed in skeletal muscles, especially in fast&#x2010;twitch fibers. CASQ2 is a component of slow&#x2010;twitch skeletal muscle and is present in cardiomyocytes.<xref rid="ccr36689-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p>
      <p>With high capacity and low affinity for Ca<sup>2+</sup>, CASQ1 plays a significant role in maintaining a large amount of Ca<sup>2+</sup> necessary for muscle contraction. It is able to dual&#x2010;directionally regulate the ryanodine receptors (RyRs) calcium release channels, likely through interactions with junctin and triadin in a complex quaternary structure to preserve the intracellular SR Ca<sup>2+</sup> storage.<xref rid="ccr36689-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Also, CASQ1 can reversely regulate the store&#x2010;operated Ca<sup>2+</sup> entry (SOCE) pathway by inhibiting stromal interaction molecule 1 (STIM1)/calcium release&#x2010;activated calcium channel protein 1 (Orai1) interaction to reduce extracellular Ca<sup>2+</sup> entries.<xref rid="ccr36689-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> Depending on the intraluminal SR Ca<sup>2+</sup> levels, CASQ1 monomers assemble to form large polymers,<xref rid="ccr36689-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> which function as a pivotal factor in buffering Ca<sup>2+</sup> in the SR terminal cisternae, thus keeping a large&#x2010;capacity reserve that can be released on stimulus to evoke muscle contraction.</p>
      <p>Mutations in <italic toggle="yes">CASQ1</italic> have been associated with two forms of myopathy. A founder mutation (c.731A&#x2009;&gt;&#x2009;G, p.Asp244Gly) was first reported in a group of patients presented with vacuolar myopathy with accumulation of SR protein aggregates.<xref rid="ccr36689-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Other mutations were associated with tubular aggregate myopathy.<xref rid="ccr36689-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="ccr36689-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="ccr36689-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> In the present case, we identified one novel mutant of <italic toggle="yes">CASQ1</italic> with peculiar clinical and ultrastructural features that had not been reported before, and also summarized previously reported <italic toggle="yes">CASQ1</italic> mutations in order to give researchers a better understanding of CASQ1 in the pathophysiological status of skeletal muscle.</p>
    </sec>
    <sec id="ccr36689-sec-0002">
      <label>2</label>
      <title>CASE REPORT</title>
      <p>A 42&#x2010;year&#x2010;old Chinese female patient came to our neuromuscular center because of slowly progressive weakness for 12&#x2009;years. Around 30&#x2009;years of age, she began to notice difficulties opening hair claws, while other daily activities were not affected. The symptoms gradually progressed and after a year she had difficulties in fist clenching. By 36&#x2009;years of age, she could not lift her arms overhead. She was born to non&#x2010;consanguineous parents and without a remarkable family history of neuromuscular disease.</p>
      <p>Physical examinations revealed mild right scapular winging, severe weakness (Medical Research Council, MRC grade 2/5) of distal upper limb muscles and relatively slight weakness (MRC 4&#x2212;/5) of scapular and proximal upper muscles, while lower limb muscles were spared (Table&#xA0;<xref rid="ccr36689-supitem-0001" ref-type="supplementary-material">S1</xref>). She had prominent atrophy of ulnar forearm muscles. Her tendon reflexes were normal. There was no myalgia, sensory disturbance, or muscle cramps. Serum creatine kinase (CK) level was within normal range (80.9&#xA0;IU/L, normal range 40.0&#x2013;200.0&#xA0;IU/L).</p>
      <p>Electromyography (EMG) analysis revealed numerous complex repetitive discharges and myotonic discharges in bilateral biceps brachii muscles. Compound motor action potentials of biceps brachii were of high mixed with low amplitude, long mixed with short duration. Nerve conduction studies and electrocardiogram were unremarkable. Muscle biopsy of the left biceps brachii showed myopathic features including increased fiber size variation, occasional necrotic fibers (Figure&#xA0;<xref rid="ccr36689-fig-0001" ref-type="fig">1B</xref>), mild myofibrillar disarrays, and moth&#x2010;eaten fibers (Figure&#xA0;<xref rid="ccr36689-fig-0001" ref-type="fig">1C</xref>). Hematoxylin and eosin (HE) stain also demonstrated optically empty vacuoles and fine eosinophilic granules in myofibers (Figure&#xA0;<xref rid="ccr36689-fig-0001" ref-type="fig">1A</xref>). There was type I fiber predominance with type II fiber atrophy (Figure&#xA0;<xref rid="ccr36689-fig-0001" ref-type="fig">1D</xref>).</p>
      <fig position="float" fig-type="FIGURE" id="ccr36689-fig-0001">
        <label>FIGURE 1</label>
        <caption>
          <p>Myopathological findings of the present case. Representative light microscopy images of muscle biopsy (A,B) Hematoxylin and eosin (HE) staining showed eosinophilic granules (arrows) scattered in myofibers and necrotic fibers. (C) Nicotinamide adenine dinucleotide (NADH) staining showed moth&#x2010;eaten fiber (arrowhead). (D) Cytochrome C oxidase, adenosine triphosphatase (ATPase) staining demonstrated a small grouping of type I fibers, with mild atrophy of type II fibers. Scale bars: 50&#x2009;&#x3BC;m (A&#x2013;C), 200&#x2009;&#x3BC;m (D).</p>
        </caption>
        <graphic xlink:href="CCR3-10-e6689-g003" position="anchor" id="jats-graphic-3"/>
      </fig>
      <p>NGS analysis (YULONG DIAGNOSTICS) covering 139 genes associated with neuromuscular disorders identified a novel heterozygous mutation in the sixth exon of <italic toggle="yes">CASQ1</italic> (NM_001231.4:c.766G&#x2009;&gt;&#x2009;A, p.Val256Met), causing a replacement of valine with methionine at amino acid position 256 of CASQ1 (Figure&#xA0;<xref rid="ccr36689-fig-0002" ref-type="fig">2A</xref>). Sequence conservation analysis identified that this valine at position 256 was conserved across different species (Figure&#xA0;<xref rid="ccr36689-fig-0002" ref-type="fig">2B</xref>). This residue constitutes a helical region starting from position 249 to 258 of CASQ1, which has not been identified with special function. Based on the predicted values of PolyPhen&#x2010;2 (<ext-link xlink:href="http://genetics.bwh.harvard.edu/pph2/" ext-link-type="uri">http://genetics.bwh.harvard.edu/pph2/</ext-link>), SIFT (<ext-link xlink:href="http://sift.jcvi.org/" ext-link-type="uri">http://sift.jcvi.org/</ext-link>), and MutationTaster (<ext-link xlink:href="http://mutpred.mutdb.org/" ext-link-type="uri">http://mutpred.mutdb.org/</ext-link>), c.766G&#x2009;&gt;&#x2009;A (p. Val256Met) was deemed pathogenic (Table&#xA0;<xref rid="ccr36689-supitem-0001" ref-type="supplementary-material">S2</xref>). This result concurred with destabilizing effects predicted by I&#x2010;Mutant3.0 (<ext-link xlink:href="http://gpcr2.biocomp.unibo.it/" ext-link-type="uri">http://gpcr2.biocomp.unibo.it/</ext-link>) and Mupro (<ext-link xlink:href="http://mupro.proteomics.ics.uci.edu/" ext-link-type="uri">http://mupro.proteomics.ics.uci.edu/</ext-link>) (Table&#xA0;<xref rid="ccr36689-supitem-0001" ref-type="supplementary-material">S3</xref>). Predictions of secondary structure using SOPMA (<ext-link xlink:href="https://npsa-prabi.ibcp.fr/" ext-link-type="uri">https://npsa&#x2010;prabi.ibcp.fr/</ext-link>) showed the mutation to induce an increased tendency to form extended strand and beta turn, while conversely on alpha helix (Table&#xA0;<xref rid="ccr36689-supitem-0001" ref-type="supplementary-material">S4</xref>).</p>
      <fig position="float" fig-type="FIGURE" id="ccr36689-fig-0002">
        <label>FIGURE 2</label>
        <caption>
          <p>Reported myopathy&#x2010;associated mutations in <italic toggle="yes">CASQ1</italic>. (A) DNA sequencing of <italic toggle="yes">CASQ1</italic> from the patient. A heterozygous missense mutation (c.766G&#x2009;&gt;&#x2009;A, p.Val256Met) was identified (red arrow). (B) Multiple amino acid sequence alignment of CASQ1. The p.Val256Met mutation occurred at an valine (V) residue that was evolutionarily conserved. (C) Schematic structure of the <italic toggle="yes">CASQ1</italic> gene. Exons were shown as boxes, with translated regions shown in black and untranslated regions shown in light gray. The p.Val256Met mutation was found in exon 6. (Red label represented the novel mutation, purple labels represented protein aggregate myopathy (PAM) related mutations in <italic toggle="yes">CASQ1</italic>, and blue labels represented tubular aggregate myopathy (TAM) related mutations in <italic toggle="yes">CASQ1</italic>).</p>
        </caption>
        <graphic xlink:href="CCR3-10-e6689-g002" position="anchor" id="jats-graphic-5"/>
      </fig>
    </sec>
    <sec sec-type="discussion" id="ccr36689-sec-0003">
      <label>3</label>
      <title>DISCUSSION</title>
      <p>To date, only five <italic toggle="yes">CASQ1</italic> mutations associated with neuromuscular disorders have been reported (Table&#xA0;<xref rid="ccr36689-tbl-0001" ref-type="table">1</xref>, Figure&#xA0;<xref rid="ccr36689-fig-0002" ref-type="fig">2C</xref>). In 2014, Rossi et al.<xref rid="ccr36689-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> reported the first <italic toggle="yes">CASQ1</italic> mutation, c.731A&#x2009;&gt;&#x2009;G (p.Asp244Gly) in eight patients characterized by mild proximal weakness, fatigue, and large vacuoles containing aggregation of SR proteins. Subsequently, Lewis et al.,<xref rid="ccr36689-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> D'Adamo et al.<xref rid="ccr36689-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> and Semplicini et al.<xref rid="ccr36689-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> identified the similar phenotype in patients with c.731A&#x2009;&gt;&#x2009;G (p.Asp244Gly). In these patients, sarcoplasmic vacuolar aggregations and reduced Ca<sup>2+</sup> release from the SR induced by abnormal CASQ1 aggregates were observed. They were thus diagnosed with protein aggregate myopathy (PAM). The pathogenesis of PAM was proposed as the the loss of the electric charge in aspartic acid at position 244. This location is not only a conserved high&#x2010;affinity Ca<sup>2+</sup> binding site but is also close to an interaction region for the adjacent CASQ1 monomers, thus the mutant leading to an increased propensity to form insoluble polymers with reduced Ca<sup>2+</sup> binding ability.<xref rid="ccr36689-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</p>
      <table-wrap position="float" id="ccr36689-tbl-0001" content-type="TABLE">
        <label>TABLE 1</label>
        <caption>
          <p>
<italic toggle="no">CASQ1</italic> mutations in previous studies associated with neuromuscular disorders</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <thead valign="bottom">
            <tr style="border-bottom:solid 1px #000000">
              <th align="left" valign="bottom" rowspan="1" colspan="1">Mutation</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Exon</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Genetics</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Disease classification</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Clinicopathological features</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Proposed mechanism</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">References</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">c.731A&#x2009;&gt;&#x2009;G (p.Asp244Gly)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">6</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Heterozygous</td>
              <td align="left" valign="top" rowspan="1" colspan="1">PAM</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>i. Myalgia, exercise intolerance, mild proximal weakness, and muscle cramping, with elevated plasma creatine kinase (CK) levels</p>
<p>ii. Optically empty vacuoles involving aggregation of sarcoplasmic reticulum (SR) proteins, almost exclusively in type II fibers</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Loss of the electric charge in D244, which resulting in increased propensity to form insoluble polymers with reduced Ca<sup>2+</sup> binding ability</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ccr36689-bib-0005" ref-type="bibr">5</xref>, <xref rid="ccr36689-bib-0009" ref-type="bibr">9</xref>, <xref rid="ccr36689-bib-0010" ref-type="bibr">10</xref>, <xref rid="ccr36689-bib-0011" ref-type="bibr">11</xref>
</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">c.130G&#x2009;&gt;&#x2009;A (p.Asp44Asn)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Heterozygous</td>
              <td align="left" valign="top" rowspan="1" colspan="1">TAM</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>i. Muscle fatigue and diffuse exercise&#x2010;induced myalgia</p>
<p>ii.Cytoplasmic aggregates of swollen membranous tubules</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Decreased Ca<sup>2+</sup> dependent polymerization leading to decreased Ca<sup>2+</sup> binding ability and a reduced inhibitary effect on SOCE</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ccr36689-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">c.166A&#x2009;&gt;&#x2009;T (p.Asn56Tyr)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Heterozygous</td>
              <td align="left" valign="top" rowspan="1" colspan="1">TAM</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>i. Progressive muscle weakness in proximal muscles of lower limbs</p>
<p>ii. Tubular aggregates</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Decreased Ca<sup>2+</sup> dependent polymerization</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ccr36689-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">c.308G&#x2009;&gt;&#x2009;A (p.Gly103Asp)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">2</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Heterozygous</td>
              <td align="left" valign="top" rowspan="1" colspan="1">TAM</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>i. Exercise intolerance, post&#x2010;exercise myalgia, stiffness, and early fatigue</p>
<p>ii. Vacuoles filled with amorphous material, consistent with tubular aggregates, only in type II fibers</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Decreased Ca<sup>2+</sup> dependent polymerization leading to decreased Ca<sup>2+</sup> binding ability</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ccr36689-bib-0007" ref-type="bibr">7</xref>, <xref rid="ccr36689-bib-0008" ref-type="bibr">8</xref>, <xref rid="ccr36689-bib-0009" ref-type="bibr">9</xref>
</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">c.1154&#x2009;T&#x2009;&gt;&#x2009;C (p.Ile385Thr)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">11</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Heterozygous</td>
              <td align="left" valign="top" rowspan="1" colspan="1">TAM</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>i. Myalgia and proximal muscle weakness</p>
<p>ii. Tubular aggregates</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Moderately increased Ca<sup>2+</sup> dependent polymerization leading to decreased Ca<sup>2+</sup> binding ability and a reduced inhibitary effect on SOCE</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="ccr36689-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot id="ccr36689-ntgp-0001">
          <fn id="ccr36689-note-0001">
            <p>Abbreviations: PAM, Protein aggregate myopathy; TAM, Tubular aggregate myopathy.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Additionally, several heterozygous missense mutations in <italic toggle="yes">CASQ1</italic> (c.130G&#x2009;&gt;&#x2009;A, c.166A&#x2009;&gt;&#x2009;T, c.308G&#x2009;&gt;&#x2009;A, and c.1154&#x2009;T&#x2009;&gt;&#x2009;C) were reported in patients with tubular aggregate myopathy (TAM).<xref rid="ccr36689-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="ccr36689-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="ccr36689-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Patients presented with muscle fatigue, exercise intolerance, post&#x2010;exercise myalgia, and proximal muscle weakness. TAM was first attributed to mutations in <italic toggle="yes">STIM1</italic> and <italic toggle="yes">ORAI1</italic>,<xref rid="ccr36689-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> along with the dysregulation of SOCE. Despite the similar phenotype, these cases showed pathological changes different from the ones with c.731A&#x2009;&gt;&#x2009;G mutation. They were characterized by vacuoles filled with numerous SR proteins including sarco&#x2010;endoplasmic reticulum Ca<sup>2+</sup> ATPase (SERCA), STIM1, ORAI1, and CASQ1,<xref rid="ccr36689-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> consistent with tubular aggregate pathology in muscle fibers. Functional studies by Barone et al.<xref rid="ccr36689-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> showed an increase in Ca<sup>2+</sup>&#x2010;dependent aggregation for the CASQ1 protein with c.1154&#x2009;T&#x2009;&gt;&#x2009;C mutation, and a reduced Ca<sup>2+</sup>&#x2010;dependent aggregation for c.130G&#x2009;&gt;&#x2009;A and c.308G&#x2009;&gt;&#x2009;A mutants. Remarkably, c.130G&#x2009;&gt;&#x2009;A and c.1154&#x2009;T&#x2009;&gt;&#x2009;C mutants were shown to possess a reduced inhibition of SOCE comparable to the wild type of CASQ1, further corroborating the imbalance of Ca<sup>2+</sup> homeostasis and SOCE both leading to the occurrence of TAM.</p>
      <p>In terms of clinical manifestation, the majority of patients reported to date presented with progressive yet mild proximal weakness. In rare cases, hyperCKaemia was the sole overt manifestation.<xref rid="ccr36689-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> By contrast, our patient displayed distal weakness that was confined to upper limbs throughout more than 10&#x2009;years progression. Her CK levels remained constantly within normal range, which might partially explain the slow progression rate. Muscle atrophy was limited to the ulnar forearms, which was different from previously described patients with prominent atrophy involving the quadriceps, scapular muscles, or pectoral muscles.<xref rid="ccr36689-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> This patient did not have the mild hypertrophy as reported in some cases.<xref rid="ccr36689-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="ccr36689-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Despite experimental evidence suggesting that CASQ1 deficiency is causally related to malignant hyperthermia&#x2010;like arrhythmia, respiratory and cardiac insufficiency have rarely appeared in CASQ1&#x2010;related cases.<xref rid="ccr36689-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Our patient did not show any evidence of respiratory or heart involvement either. It is important to underline that atypical granules stained red with HE were detected to discrete in myofibers in large quantities, which has not been observed in other patients with <italic toggle="yes">CASQ1</italic> mutations. The mechanism of these abnormal eosinophilic granules remained unknown, but it was believed to have connections with the decreased stability in CASQ1, and might be a new pathological phenotype of PAM. We also found a few optically empty vacuoles which was similar to the one observed in c.731A&#x2009;&gt;&#x2009;G mutant, but far less than that in distribution.<xref rid="ccr36689-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>
</p>
    </sec>
    <sec sec-type="conclusions" id="ccr36689-sec-0004">
      <label>4</label>
      <title>CONCLUSION</title>
      <p>In summary, we report the first patient from China with CASQ1&#x2010;related myopathy due to a novel heterozygous mutation (c.766G&#x2009;&gt;&#x2009;A, p.Val256Met). This is also the first CASQ1 case with predominant distal upper limb weakness, starting from distal compartment and later involving proximal extremities, and her serum CK was throughout within normal range. This patient is featured by atypical eosinophilic granules on muscle pathology, which might be a new pathological phenotype of PAM. Finally, we have reviewed all pathogenic mutations in <italic toggle="yes">CASQ1</italic> to date and summarized their genetic and clinical characteristics. Our study expands the phenotypic spectrum of CASQ1&#x2010;related myopathy and further studies should be performed to explore the mechanisms operated by CASQ1 in maintaining skeletal muscle Ca<sup>2+</sup> homeostasis.</p>
    </sec>
    <sec id="ccr36689-sec-0005">
      <title>AUTHOR CONTRIBUTIONS</title>
      <p>HY and YL conceived the idea and revised the literature. KZ interpreted the results and wrote the manuscript. HD, QL, LX, and KH participated in the clinical management and data collection. GZ performed the data analysis. All authors read and approved the final version of the manuscript.</p>
    </sec>
    <sec id="ccr36689-sec-0007">
      <title>FUNDING INFORMATION</title>
      <p>This work was supported by National Natural Science Foundation of China (grant number 81601094).</p>
    </sec>
    <sec sec-type="COI-statement" id="ccr36689-sec-0008">
      <title>CONFLICT OF INTEREST</title>
      <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
    </sec>
    <sec sec-type="conclusions" id="ccr36689-sec-0009">
      <title>CONSENT</title>
      <p>Written informed consent was obtained from the patient to publish this report in accordance with the journal's patient consent policy.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supporting information</title>
      <supplementary-material id="ccr36689-supitem-0001" position="float" content-type="local-data">
        <caption>
          <p>
Appendix S1
</p>
        </caption>
        <media xlink:href="CCR3-10-e6689-s001.docx">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="ccr36689-sec-0006">
      <title>ACKNOWLEDGMENT</title>
      <p>The authors thank the patient and her families for their support.</p>
    </ack>
    <sec sec-type="data-availability" id="ccr36689-sec-0011">
      <title>DATA AVAILABILITY STATEMENT</title>
      <p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p>
    </sec>
    <ref-list content-type="cited-references" id="ccr36689-bibl-0001">
      <title>REFERENCES</title>
      <ref id="ccr36689-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="ccr36689-cit-0001">
<string-name>
<surname>MacLennan</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>PT</given-names>
</string-name>. <article-title>Isolation of a calcium&#x2010;sequestering protein from sarcoplasmic reticulum</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1971</year>;<volume>68</volume>(<issue>6</issue>):<fpage>1231</fpage>&#x2010;<lpage>1235</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.68.6.1231</pub-id>
<pub-id pub-id-type="pmid">4256614</pub-id></mixed-citation>
      </ref>
      <ref id="ccr36689-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="ccr36689-cit-0002">
<string-name>
<surname>Lamboley</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>McKenna</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Lamb</surname>
<given-names>GD</given-names>
</string-name>. <article-title>Endogenous and maximal sarcoplasmic reticulum calcium content and calsequestrin expression in type I and type II human skeletal muscle fibres</article-title>. <source>J Physiol</source>. <year>2013</year>;<volume>591</volume>(<issue>23</issue>):<fpage>6053</fpage>&#x2010;<lpage>6068</lpage>. doi:<pub-id pub-id-type="doi">10.1113/jphysiol.2013.265900</pub-id>
<pub-id pub-id-type="pmid">24127619</pub-id></mixed-citation>
      </ref>
      <ref id="ccr36689-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="ccr36689-cit-0003">
<string-name>
<surname>Wei</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Gallant</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Dulhunty</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Beard</surname>
<given-names>NA</given-names>
</string-name>. <article-title>Junctin and triadin each activate skeletal ryanodine receptors but junctin alone mediates functional interactions with calsequestrin</article-title>. <source>Int J Biochem Cell Biol</source>. <year>2009</year>;<volume>41</volume>(<issue>11</issue>):<fpage>2214</fpage>&#x2010;<lpage>2224</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biocel.2009.04.017</pub-id>
<pub-id pub-id-type="pmid">19398037</pub-id></mixed-citation>
      </ref>
      <ref id="ccr36689-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="ccr36689-cit-0004">
<string-name>
<surname>Wang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Retrograde regulation of STIM1&#x2010;Orai1 interaction and store&#x2010;operated Ca2+ entry by calsequestrin</article-title>. <source>Sci Rep</source>. <year>2015</year>;<volume>5</volume>:<elocation-id>11349</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/srep11349</pub-id>
<pub-id pub-id-type="pmid">26087026</pub-id></mixed-citation>
      </ref>
      <ref id="ccr36689-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="ccr36689-cit-0005">
<string-name>
<surname>Rossi</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Vezzani</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Galli</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>A mutation in the CASQ1 gene causes a vacuolar myopathy with accumulation of sarcoplasmic reticulum protein aggregates</article-title>. <source>Hum Mutat</source>. <year>2014</year>;<volume>35</volume>(<issue>10</issue>):<fpage>1163</fpage>&#x2010;<lpage>1170</lpage>. doi:<pub-id pub-id-type="doi">10.1002/humu.22631</pub-id>
<pub-id pub-id-type="pmid">25116801</pub-id></mixed-citation>
      </ref>
      <ref id="ccr36689-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="ccr36689-cit-0006">
<string-name>
<surname>Di Blasi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sansanelli</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ruggieri</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>A CASQ1 founder mutation in three Italian families with protein aggregate myopathy and hyperCKaemia</article-title>. <source>J Med Genet</source>. <year>2015</year>;<volume>52</volume>(<issue>9</issue>):<fpage>617</fpage>&#x2010;<lpage>626</lpage>. doi:<pub-id pub-id-type="doi">10.1136/jmedgenet-2014-102882</pub-id>
<pub-id pub-id-type="pmid">26136523</pub-id></mixed-citation>
      </ref>
      <ref id="ccr36689-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="ccr36689-cit-0007">
<string-name>
<surname>Barone</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Del Re</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Gamberucci</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Identification and characterization of three novel mutations in the CASQ1 gene in four patients with tubular aggregate myopathy</article-title>. <source>Hum Mutat</source>. <year>2017</year>;<volume>38</volume>(<issue>12</issue>):<fpage>1761</fpage>&#x2010;<lpage>1773</lpage>. doi:<pub-id pub-id-type="doi">10.1002/humu.23338</pub-id>
<pub-id pub-id-type="pmid">28895244</pub-id></mixed-citation>
      </ref>
      <ref id="ccr36689-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="ccr36689-cit-0008">
<string-name>
<surname>B&#xF6;hm</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lornage</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Chevessier</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>CASQ1 mutations impair calsequestrin polymerization and cause tubular aggregate myopathy</article-title>. <source>Acta Neuropathol</source>. <year>2018</year>;<volume>135</volume>(<issue>1</issue>):<fpage>149</fpage>&#x2010;<lpage>151</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00401-017-1775-x</pub-id>
<pub-id pub-id-type="pmid">29039140</pub-id></mixed-citation>
      </ref>
      <ref id="ccr36689-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="journal" id="ccr36689-cit-0009">
<string-name>
<surname>Semplicini</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bertolin</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bello</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>The clinical spectrum of CASQ1&#x2010;related myopathy</article-title>. <source>Neurology</source>. <year>2018</year>;<volume>91</volume>(<issue>17</issue>):<fpage>e1629</fpage>&#x2010;<lpage>e1641</lpage>. doi:<pub-id pub-id-type="doi">10.1212/wnl.0000000000006387</pub-id>
<pub-id pub-id-type="pmid">30258016</pub-id></mixed-citation>
      </ref>
      <ref id="ccr36689-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal" id="ccr36689-cit-0010">
<string-name>
<surname>Lewis</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Ronish</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>R&#xED;os</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kang</surname>
<given-names>C</given-names>
</string-name>. <article-title>Characterization of two human skeletal Calsequestrin mutants implicated in malignant hyperthermia and vacuolar aggregate myopathy</article-title>. <source>J Biol Chem</source>. <year>2015</year>;<volume>290</volume>(<issue>48</issue>):<fpage>28665</fpage>&#x2010;<lpage>28674</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M115.686261</pub-id>
<pub-id pub-id-type="pmid">26416891</pub-id></mixed-citation>
      </ref>
      <ref id="ccr36689-bib-0011">
        <label>11</label>
        <mixed-citation publication-type="journal" id="ccr36689-cit-0011">
<string-name>
<surname>D'Adamo</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Sforna</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Visentin</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>A Calsequestrin&#x2010;1 mutation associated with a skeletal muscle disease alters sarcoplasmic Ca2+ release</article-title>. <source>PLoS One</source>. <year>2016</year>;<volume>11</volume>(<issue>5</issue>):<elocation-id>e0155516</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0155516</pub-id>
<pub-id pub-id-type="pmid">27196359</pub-id></mixed-citation>
      </ref>
      <ref id="ccr36689-bib-0012">
        <label>12</label>
        <mixed-citation publication-type="journal" id="ccr36689-cit-0012">
<string-name>
<surname>B&#xF6;hm</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Chevessier</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Maues De Paula</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Constitutive activation of the calcium sensor STIM1 causes tubular&#x2010;aggregate myopathy</article-title>. <source>Am J Hum Genet</source>. <year>2013</year>;<volume>92</volume>(<issue>2</issue>):<fpage>271</fpage>&#x2010;<lpage>278</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajhg.2012.12.007</pub-id>
<pub-id pub-id-type="pmid">23332920</pub-id></mixed-citation>
      </ref>
      <ref id="ccr36689-bib-0013">
        <label>13</label>
        <mixed-citation publication-type="journal" id="ccr36689-cit-0013">
<string-name>
<surname>Boncompagni</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lopez</surname>
<given-names>JR</given-names>
</string-name>, et al. <article-title>Triadin/Junctin double null mouse reveals a differential role for Triadin and Junctin in anchoring CASQ to the jSR and regulating Ca(2+) homeostasis</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>7</issue>):<elocation-id>e39962</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0039962</pub-id>
<pub-id pub-id-type="pmid">22768324</pub-id></mixed-citation>
      </ref>
      <ref id="ccr36689-bib-0014">
        <label>14</label>
        <mixed-citation publication-type="journal" id="ccr36689-cit-0014">
<string-name>
<surname>Sun</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Functional Calsequestrin&#x2010;1 is expressed in the heart and its deficiency is causally related to malignant hyperthermia&#x2010;like arrhythmia</article-title>. <source>Circulation</source>. <year>2021</year>;<volume>144</volume>(<issue>10</issue>):<fpage>788</fpage>&#x2010;<lpage>804</lpage>. doi:<pub-id pub-id-type="doi">10.1161/circulationaha.121.053255</pub-id>
<pub-id pub-id-type="pmid">34162222</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>